Although investigators were asked to specify the type of therapy (eg, systemic chemotherapy vs allogeneic stem cell transplant), details of the therapy (eg, type of conditioning regimen for a transplant) were not prospectively collected. An Amonafide (AS1413) independent data monitoring committee assessed the safety of study participants during the trial and monitored the overall study conduct. == Statistical analysis == Data were analyzed by representatives of Seattle Genetics, Inc., and all authors had access to the primary clinical trial data. The primary end point of the trial was objective response rate (ORR) per the independent review facility (IRF). this group (medians not reached). Of the 34 patients who obtained CR, 16 (47%) remain progression-free after a median of 53. 3 months (range, 29. 0 to 56. 2 months) of observation; 12 patients remain progression-free without a consolidative allogeneic stem cell transplant. Younger age, good performance status, and lower disease burden at baseline were characteristic of patients who achieved a CR and were favorable prognostic factors for overall survival. These results suggest that a significant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease control. The trial was registered atwww.clinicaltrials.govas #NCT00848926. == Introduction == The standard of CANPL2 care for patients with relapsed or refractory Hodgkin lymphoma (HL) is salvage chemotherapy followed by autologous stem cell transplant (auto-SCT) in responding patients, which is curative in approximately half of those who undergo the procedure. The ability to achieve and maintain a complete remission (CR) prior to transplant has emerged as a factor important for a favorable progression-free and overall survival Amonafide (AS1413) (OS) after transplant. 1, 2 Unfortunately, approximately 50% of patients will experience relapse or Amonafide (AS1413) progression after auto-SCT. Amonafide (AS1413) For this population, outcomes have historically been poor, with median OS rates from time of relapse ranging from 10. 5 months to 27. 6 months. 3, 4Although reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) can induce long-term progression-free survival (PFS), and in some cases secondary cure, in a subset of patients who relapse following auto-SCT, its use is associated with high rates of progression and nonrelapse mortality. 5 Brentuximab vedotin (ADCETRIS) is composed of an anti-CD30 antibody conjugated by a protease cleavable linker to monomethyl auristatin E, a microtubule-disrupting agent. In a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory HL after auto-SCT, 75% of patients achieved an objective response (95% confidence interval [CI]: 64. 9%, 82. 6%) and 34% of patients achieved CR (95% CI: 25. 2%, 44. 4%) per independent central review. 6The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. Herein, we present response durability and survival in this trial population after a median follow-up period of approximately 3 years. Factors associated with durable remissions and favorable survival are explored. == Methods == == Patient eligibility == Eligible patients were aged 12 years or older with relapsed or refractory HL after auto-SCT. Histologic confirmation of CD30-positive Hodgkin Reed-Sternberg cells by central pathology review was required, as well as fluorodeoxyglucose-avid disease by positron emission tomography (PET) and measurable disease of at least 1 . 5 cm by computed tomography (CT). Patients who had received a prior allo-SCT were ineligible. Additional eligibility criteria are reported by Younes et al. 6 == Study design and treatment == A complete description of this open-label, phase 2, single-arm study has been previously reported. 6Briefly, this clinical trial was conducted at 25 centers within the United States, Canada, and Europe and was approved by each investigational sites institutional review board or ethics committee. Patients were recruited between February and August 2009, and all patients provided written informed consent. Patients received brentuximab vedotin 1 . 8 mg/kg IV once every 3 weeks over 30 minutes on an outpatient basis for up to 16 infusions. == Study assessments == Clinical response was determined both by investigators and by an independent central review facility (Bioclinica, formerly known as CoreLab Partners and RadPharm; Princeton, NJ) according to the Revised Response Criteria for Malignant Lymphoma. 7Patients were assessed for response by CT at cycles 2, 4, 7, 10, 13, and 16 and by PET at cycles 4 and 7. During the long-term follow-up period, all patients were followed for survival every 3 months during years 1 to 2, every 6 months during years 3 to 5, and annually thereafter. Patients who discontinued study treatment for any reason other than progressive disease or initiation of new anticancer therapy were also evaluated on this plan for radiographic progression. Amonafide (AS1413) In October 2013, the protocol was changed to need a CT search within only if development was thought clinically. During the rewrite, 18 sufferers were continue to being evaluated for development; these sufferers had been in long-term followup for a median of more than 30 a few months. Investigators were also asked to record whether patients got initiated new cancer-related therapy during the long lasting follow-up period. Although researchers were asked to identify the type of therapy (eg, systemic chemotherapy versus allogeneic originate cell transplant), details of the therapy (eg, kind of conditioning routine for.